Kim Biermann
University of Bonn
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Kim Biermann.
The Journal of Nuclear Medicine | 2010
Hojjat Ahmadzadehfar; Amir Sabet; Kim Biermann; Marianne Muckle; Holger Brockmann; Christiane K. Kuhl; Kai Wilhelm; Hans-Jürgen Biersack; Samer Ezziddin
Selective internal radiation therapy (SIRT), a catheter-based liver-directed modality for treating primary and metastatic liver cancer, requires appropriate planning to maximize its therapeutic response and minimize its side effects. 99mTc-macroaggregated albumin (MAA) scanning should precede the therapy to detect any extrahepatic shunting to the lung or gastrointestinal tract. Our aim was to compare the ability of SPECT/CT with that of planar imaging and SPECT in the detection and localization of extrahepatic 99mTc-MAA accumulation and to evaluate the impact of SPECT/CT on SIRT treatment planning and its added value to angiography in this setting. Methods: Ninety diagnostic hepatic angiograms with 99mTc-MAA were obtained for 76 patients with different types of cancer. All images were reviewed retrospectively for extrahepatic MAA deposition in the following order: planar, non–attenuation-corrected SPECT, and SPECT/CT. Review of angiograms and follow-up of patients with abdominal shunting served as reference standards. Results: Extrahepatic accumulation was detected by planar imaging, SPECT, and SPECT/CT in 12%, 17%, and 42% of examinations, respectively. The sensitivity for detecting extrahepatic shunting with planar imaging, SPECT, and SPECT/CT was 32%, 41%, and 100%, respectively; specificity was 98%, 98%, and 93%, respectively. The respective positive predictive values were 92%, 93%, and 89%, and the respective negative predictive values were 71%, 73%, and 100%. The therapy plan was changed according to the results of planar imaging, SPECT, and SPECT/CT in 7.8%, 8.9%, and 29% of patients, respectively. Conclusion: In pre-SIRT planning, 99mTc-MAA SPECT/CT is valuable for identifying extrahepatic visceral sites at risk for postradioembolization complications.
Psychiatry Research-neuroimaging | 2009
Holger Brockmann; Astrid Zobel; Alexius Joe; Kim Biermann; Lukas Scheef; Anna Schuhmacher; Olrik von Widdern; Martin Metten; Hans-Juergen Biersack; Wolfgang Maier; Henning Boecker
Alterations of regional cerebral blood flow (rCBF) in prefrontal cortex and the anterior cingulate cortex are conspicuous imaging findings in patients with major depression (MD). While these rCBF changes have been suggested as functional disease markers, data in large patient samples examining treatment response prediction to antidepressant therapy are limited. This study examined the predictive value of Tc-99m-HMPAO-SPECT for subsequent treatment response to antidepressant therapy with citalopram in an unprecedented large collective of patients. Ninety-three patients with MD were examined with Tc-99m-HMPAO-SPECT twice, at the beginning of citalopram-treatment (T1) and after 4 weeks of treatment (T2). To determine the impact of rCBF changes associated with treatment response, the patient sample was divided into two subgroups: responders (44 patients) and non-responders (49 patients). A two-sample t-test was used to determine group-specific rCBF-differences. Age, gender and initial Hamilton Rating Scale for Depression (HRSD) were treated as regressors of no interest. The responder group revealed significant relative rCBF increases at T1 in a large region en-compassing predominantly prefrontal and temporal cortices as well as subgenual cingulate cortex. No relative rCBF decreases were detected in this group. The comparison between T1 and T2 revealed trends of rCBF decreases in inferior frontal gyrus and rCBF increases in premotor cortex in the responder group. Our data show that rCBF measurements with TC-99M-HMPAO-SPECT provide a predictor estimate for subsequent treatment response in depressed patients undergoing antidepressant therapy with citalopram. This effect is highly significant and, most notably, independent of the initial HRSD score.
Thrombosis and Haemostasis | 2008
Jan Bucerius; Anna Naubereit; Alexius Joe; Samer Ezziddin; Kim Biermann; Jörn Risse; Holger Palmedo; Johannes Oldenburg; Hans-Jürgen Biersack
There is little data regarding the impact of subclinical hyperthyroidism on coagulation metabolism in patients undergoing systemic anticoagulation therapy with coumarin derivates. In this retrospective analysis we studied 233 patients with benign thyroid disorders receiving therapeutic iodine-131, as well as concomitant systemic anticoagulation therapy (subclinical hyperthyroidism: n = 178; overt hyperthyroidism: n = 15; euthyroidism: n = 40). Multivariate regression analyses were performed in the total study population as well as in the subgroup of patients with subclinical hyperthyroidism to identify the possible impact of several variables on anticoagulation therapy, large enough to push the International Normalized Ratio (INR) level out of the therapeutic range (INR <2.0 or >3.0). Therapy with antibiotics or nitrates was significantly associated with INR-values >3.0 in the total population, while ACE inhibitors were associated with lower incidence of INR-values <2.0. In patients with subclinical hyperthyroidism, therapy with antibiotics was predictive of INR-values >3.0, whereas therapy with thyroid suppressive drugs or TSH-values <0.1 mU/l was associated with INR-values <2.0. Moreover, in a subgroup of 40 patients with the positive history of both subclinical hyperthyroidism and euthyroidism intraindividual comparison with regard to the possible impact on anticoagulation therapy was performed which failed to show any significant differences in INR-values between the two thyroid metabolic conditions. In conclusion, subclinical hyperthyroidism seems to have no significant impact on coagulation metabolism in patients receiving anticoagulation therapy.
Acta Radiologica | 2011
Jan Bucerius; Alexius Joe; Ellen Herder; Holger Brockmann; Kim Biermann; Holger Palmedo; Klaus Tiemann; Hans-Juergen Biersack
Background Only few data are available regarding the prognostic impact of myocardial perfusion scintigraphy with 99mTc-sestamibi (MPS) regarding emerging cardiac events in elderly patients Purpose To evaluate the prognostic value of MPS regarding emerging cardiac events in patients aged ≥70 years with known or suspected coronary artery disease (CAD). Material and Methods One hundred and thirty-three patients (74.6 ± 3.7 years) who underwent exercise or pharmacological stress/rest MPS were included in this analysis. Semi-quantitative visual interpretation of MPS images was performed and Summed-Stress- (SSS), Summed-Difference- (SDS), and Summed-Rest Scores (SRS) were calculated. Multivariate logistic regression analyses were calculated for evaluation of the independent prognostic impact of MPS results and several cardiac-related patient characteristics with regard to emerging cardiac events. Kaplan-Meier survival- and log rank analyses were calculated for assessment of cardiac event-free survival. Results Pathological SSS (OR: 3.3), angina (OR: 2.7) and ischemic ECG (OR: 3.0) were independently associated with cardiac events. Patients with pathological SSS (p = 0.005) and ischemic ECG (p = 0.012) had a significantly lower incidence of cardiac event-free survival. Conclusion Pathological MPS is independently associated with emerging cardiac events predicting a significantly lower incidence of cardiac event-free survival in patients aged ≥70 years.
European Journal of Nuclear Medicine and Molecular Imaging | 2011
Samer Ezziddin; Martin Opitz; Mared Attassi; Kim Biermann; Amir Sabet; Stefan Guhlke; Holger Brockmann; Winfried A. Willinek; Eva Wardelmann; Hans-Jürgen Biersack; Hojjat Ahmadzadehfar
Journal of Psychiatric Research | 2011
Holger Brockmann; Astrid Zobel; Anna Schuhmacher; Marcel Daamen; Alexius Joe; Kim Biermann; Sibylle G. Schwab; Hans-Juergen Biersack; Wolfgang Maier; Henning Boecker
European Journal of Nuclear Medicine and Molecular Imaging | 2017
Amir Sabet; Ina Binse; Semih Dogan; Andrea Koch; Sandra Rosenbaum-Krumme; Hans-Jürgen Biersack; Kim Biermann; Samer Ezziddin
International Journal of Cardiovascular Imaging | 2009
Jan Bucerius; Alexius Joe; Ellen Herder; Holger Brockmann; Kim Biermann; Holger Palmedo; Klaus Tiemann; Hans-Jürgen Biersack
The Journal of Nuclear Medicine | 2007
Samer Ezziddin; Mared Attassi; Stefan Guhlke; Khaled Ezziddin; Holger Palmedo; Karl Reichmann; Hojjat Ahmadzadehfar; Kim Biermann; Eric P. Krenning; Hans-Jürgen Biersack
The Journal of Nuclear Medicine | 2013
Marianne Muckle; Kim Biermann; Alexius Joe; Amir Sabet; Samer Ezziddin; Hans J. Biersack; Hojjat Ahmadzadehfar